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Students' Corner
Flow Cytometric Analysis of Childhood Lenkemias
R.Z. Yusuf, S. Pervez, S.A. Aziz; M. Khurshid
Department of Pathology, The Aga Khan Univcrsily Hospilal, Karachi.

Abstract
Objective: To collect demographic data for childhood (less than 15 years) leukemias in Karachi, describe the
accuracy of the cell surface markers routinely used in the flow cytometric analysis of leukemic cells and arrive
at an ideal panel of antibodies for analyzing leukemic samlples.
Materials and Methods: Data from 62 consecutive cases of childhood leukemias referred to the Department of

Pathology. Aga Khan University Hospital, (AKUH) between January 1995 and December 1998 was analyzed
using Epi Info Version 6. Flow cytometry on all samples was performed using standard protocols.

Results: The mean age of patients was 8.2 years and 49 (79%) were males. Fifty (81 %) had acute lymphoblastic
leukemias of which 50% were CD10 positive and 24% CD10 negative Pre-8 cell leukemias.
Among all Pre B cell All 98% were positive for CD19. 96% for CD22, 89% for HLA-DR and 67% for CD10. Of
the 10 AML cases, 100% were positive for CD33, 90% for CD13, 80% for CD19 and 70% for HLA-DR.
Conclusion: The mean age in this study population was significantly higher and percentage of CD10 positive
Pre-BAll is lower than that in the West. Both these factors might be responsible for the poorer prognosis of these
patients. It is not possible to specify a minimum or maximum panel of antibodies that should be used for
phenotyping all cases of childhood leukemias. A certain degree or redundancy is essential in any panel of
antibodies used for flow cytometry of leukemias (JPMA 51 :133;2001 ).

Introduction
Leukemias are the most common cancers in children
less than 15 years of age in Pakistan 1• Leukemias also
comprise the majority (40%) of the childhood malignancies
in the West including United States 2 Therefore, they make
up the majority of pediatric malignancies in several parts
of the world. Most of these are fortunately curable3 The
epidemiology and biology of these tumors, unlike the
incidence varies from region to region 4 ,5. This makes it
essential to ascertain the epidemiology and biology of these
tumors in our population, as has been done elsewhere 6.7. A
search o fthe past five years of literature reveals very limited
statistics relevant to Pakistan, in this regard8. To arrive at
these statistics was one of the objectives of this study.
Flow cytometric is highly applicable to the detection
and classification of leukemias because of the ease with
which single cell suspensions can be made. Composite
immunophenotypic analysis is essential for classifying
leukemias once the disease is detected by traditional
means9. Ongoing efforts to standardize protocols are
essential to ensure widespread applicability, together with
improved understanding of the attributes and limitations of
this technology.
Flow cytometric analysis of leukemic samples was
started routinely at The Aga Khan University Hospital,
Department of Pathology in 1995 since then there has been
continuous evaluation and revision of the panel of
antibodies used to analyze leukemic cells. This study also
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looks at the accuracy of the cell surface markers that have
been used routinely for analysis of leukemic samples, since
1995 to arrive at an ideal panel of antibodies for analyzing
leukemic samples.

Materials and Methods
A study question was formulated and a list of all the
records of leukemias referred to The Department of
Pathology, between January 1995 and December 1998 was
generated. Patients in the desired age group (less than 15
years) were selected and relevant information from their
records was documented on specially designed data entry
forms. The data was then entered in Epi. Info Version 6.1.
Analysis was performed using the same program. Student's
t test and Chi square test of significancies were performed
to determine the presence of a significant difference
between mean age and the percentage ofCD10 positive preS acute lymphoblastic leukemias between this study
population and Western literature. Alpha value was chosen
to be 0.05.
Flow cytometry was performed on all the peripheral
blood and bone marrow samples by centrifuging
mononuclear cells from them. These were then stained with
florescence labeled antibodies (obtained from Becton
Dickinson, U.S.A.) and run on FACSCAN using cell quest
software. The same software was used to analyze the flow
cytom etry data I 0
CDJ9, CD20, CD22, CDJO, CD3, CDS, CD7,
CD13, CD33 and HLA-DR were tested on all the cases! I
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C02 was not included in the panel because of the presence
ofCD3, CDS and CD7, which are all T cell markers as its
inclusion would have added no new information. CD14,
CD45, Anti-Kappa, Anti-Lambda, lgG, lgM and CD61
were markers that were tested on selected cases. Positivity
of a clone for a specific cell surface marker was defined as
more than 30% oft he cells staining with the antibody for the
respective marker.

Results
Data from a total of 62 cases of childhood (less than
15 years) leukemias, on which tlow cytornetry had been
perfotrned was analyzed. The mean age of patients was 8.2
years with a standard deviation of 3.9 years. Most of them
(49/62 or 79%) were males. The site from which the sample
was taken was reported in 60 (97%) cases. Of these 32
(53.3%) were peripheral blood and 28 (46.7%) bone
marrow samples.

Figure 2. Flow cytomctry of acute myclobla>tit

leuk~mia

0 CD 10 +ve Pn; 8 ALL 0 CD I 0 -ve Pre B All E1 T Cell ALL E1 Mature B Gell ALL
Figure I Flow cytometry ofCDIO positive common prc-B acute lympnobla>tic leukemia

Table I.

CDI9+ve
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Fi!,lure :1 lrnmunolog,ic

phcnoty 1 le~

of acute lyrnphobla-;tic leukemi,"; (ALL) (n· 50)

of different cell surfll.cc markers in various classes of k·ukcmias.

CD20+ve CD22+ve CDlO+ve

C03+ve

CD5+ve

CD7+ve

CD3+vc

CD33+vc

IILA-DR+vc

Total
cases

Pre·B ALL

45

21

44

31

3

6

3

T-ALL

0

0

0

0

2

3

3

0

0

0

0

0

2

2

Mature B

0

41

46

0

3

7

10

0

Cell ALL

AML

8

0

()

II

Fifty two cases (83.9%) were acute lymphoblastic
leukemias (ALL). Of these 52 cases, 59.6% were CDJO
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positive (Figure 1), 28.9% were CD I 0 negative Pre-BALL,
5.8% were T-Cell ALL and 1.9% were mature 8-Cell ALL.
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Table 2. Comparison of pcn:entagc of different subtypes of Acute
Lymphoblastic Leukemia~.

Common

Pre-B cell ALL

Our data(%)

Western data32 ('Yo)

88.5

80
15

T eel! ALL

5.8

Mature B cell ALL/others

7.7

Ten of the 62 cases were acttte myeloblastic leukemias
(AML) (Figure 2). Two cases were reported as inconclusive.
Of the 31 CD I 0 positive cases, the majority (54.8%) were
detected in bone marrow samples and 45.2% in peripheral
blood. The frequencies of the various immunophenotypes of
acute lymphoblastic leukemias are shown in Figure 3.
The cell surface markers which were positive in each
immunologic phenotype of ALL and AML are shown in
Table I.

Discussion
The mean age in this study was 8.2 years with a
standard deviation of 3.9 years. Peak incidence in the 5-9
years age group in males and the 10-14 year age group in
females I. In the West the peak age of incidence is 4 years 12
which is significantly less (p<0.05) than that seen in our
population. This could be attributed to the late presentation
of these children in our setting.
It is established that ALL is more common in males
than females, in the pediatric populationl,l2,13_ In
accordance, the majority of our patients were males. Eighty
four percent of our cases were those of ALL, the remainder
being AML, which is similar to the results reported
elsewherel3,1 4 .
A comparison of the immunologic phenotypes of
ALL in our population and in the West are shown in Table
2. The frequencies of gross categories are similar but there
is a paucity of COlO positive Pre-BALL (p<O.OS) in our
series as compared to the West and Far East 15-18 This
decrease in COlO positive Pre-BALL, (COlO being a good
prognostic indicatorl5,17J9 could account for the poorer
prognosis of leukemias in our population 20.
There was no marked excess of CD I 0 positive cells
in the bone marrow samples as compared to the peripheral
blood samples. This corroborates evidence that significant
homing mechanisms do not seem to be actively involved in
localizing COlO positive cells to the bone marrow21.
Since 1995, flow cytometry has routinely been
performed on leukemic samples at the Department of
Pathology, AKUH.
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The following is arl analysis of the accuracy of
markers commonly used for flow cytometric analysis of
leukemias at AKUH. The denominator for this analysis is
60 cases (excluding the two cases which were reported as
inconclusive). The terms "specificiy" and "sensitivity" are
not used in the strict statistical sense. Accuracy of various
markers was calculated by working out the percentage of
cells which tested positive for the markers which were
expected biologically, to be present on these cells. This
method of analysis has been used before, successfully8
CDI9 was detected on 92% ofB-Cell ALL and 80%
of AML cases. As shown earlier, CD 19 is not very specific
to B Cell leukemias10.22 CD20 was positive in 44% of
cases of B Cell ALL and was not expressed on any non B
Cell malignancy. Our study confirms that CD20 is less often
expressed on acute B lineage leukemias than CD19 but is
more "specific:' for B cell malignanciesl0,23. CD22 was
found on 90% of the B cell malignancies and on none of the
non B cell malignancies. A highly "sensitive" and "specific"
marker, CD 22' s usefulness to detect acute B-lineage
leukemias is decreased by the fact that it is often dim and is
more strongly expressed in the cytoplasm of cells than on
their surface 111.24 67% (31/46) of the cases of Pre B Cell
ALL were COl 0 positive. This is lower than the percentage
of CD!O positive Pre-B cell ALL reported in the West and
this point has been discussed above. CD 10 was not detected
on any case of T cell ALL (as has been reported in
literature IS_ This could be due to the small number of cases
ofT cell ALL in our study. We hypothesize that it could also
be due to the high socio-economic status of the patients
reporting to the Aga Khan University Hospital since T-ALL
is more common in the low socio-economic group.
However our study does not have the power to test this
hypothesis.
CD3 was detected on 66.7% of the cases ofT cell
ALL and 7% of the cases of non T cell malignancies. It is
hence a "sensitive" and "specific" marker for detecting T
cell ALL23 Its usefulness is limited by the fact that it is
uncommonly expressed on the surface ofT-lineage ALL. It
is almost always present in the cytoplasm of these cellsl0,25_
CDS was found on all 3 cases ofT cell leukemias and 12.3%
of non T cell malignancies. Our study corroborates evidence
that CDS is specific for T cells and occurs in a great
majority of cases, the drawback once again being that it is
dimly expressed 10.2 6 . CD? was seen on 4/46 cases ofPre-8
cell ALL. This was seen in samples of peripheral blood for
leukemia analysis, which normally has 80% T lymphocytes.
This pattern is most likely reactivity to normal circulating
lymphocytes. CD7 was also found on all cses ofT cell ALL
and on _14% of cases of non T cell ALL. It is reported in
literature however, that CD? is found tn cases of AML too
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and is not as "specific" for T cell ALL as our study
suggests I0,27
CD 13 was found on 90% of cases of AML and 8%
of non AML cases. CD33 was found on all cases of AML
and on 2% of non AML cases. Both these markers are hence
valuable for diagnosis of AML. Since both can occasionally
be expressed on B or T lineage ALL they should be
interpreted as strongly suggestive of myeloid leukemia only
when expressed in the absence of lymphoid associated
antigensl0,26. Our study confirms previous reports that
HLA-DR is found in most cases of AML and B lineage
ALLI0.28
In conclusion, the epidemiology of acute leukemias
·in our study population is similar to that reported in the
West. This has also been shown in another Pakistani
studies29,30. Late age at presentation and an excess of COlO
positive cases may lead to poor outcome.
Regarding flow cytometry, antibodies clearly vary in
their degree of lineage specificity. Also, many leukemias
lack one or more antigens expected to be present on normal
cells of a particular lineage9.10,31 .32. It is hence
recommended, that a certain degree of redundancy be built
into a panel for leukemia phenotyping.
Where possible it is recommended that lineage
assignment be confirmed with an antibody from a second
CD cluster which is known to react principally with the
suspected cell lineage. However, failure to detect the
confirmatory marker does not exclude the suspected lineage
since leukemias commonly exhibit loss of various antigens.
It is hence not possible to specify a minimum or maximum
pane) that should be used for phenotyping all cases of
JeukemiaslO,I4,33
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